First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus Business Wire CONCORD, Calif. -- May 28, 2013 Cerus Corporation (NASDAQ:CERS) announced today that Aalborg University Hospital, Denmark, signed a five year project collaboration agreement for the INTERCEPT Blood System for platelets. The first hospital in Denmark to adopt INTERCEPT, the department of FBE Klinisk Immunologi at Aalborg University Hospital transfuses an estimated 2,200 platelet units annually to Region Nordjylland, representing approximately 6% of Denmark’s platelet market. “Bacterial contamination of platelets is one of the most prevalent infectious risks in blood transfusion, posing serious health risks to transfusion patients. We believe the INTERCEPT Blood system will significantly decrease residual risk due to bacterial contamination, and offer key operational advantages such as reduced waste rates,” stated Dr. Kim Varming of the department of FBE Klinisk Immunologi. “We are extremely pleased with Aalborg University Hospital's position on blood safety, as shown by its proactive approach to protecting their patients against transfusion transmitted infections,” said Caspar Hogeboom, president of Cerus Europe. “Through 10 years of routine use, INTERCEPT demonstrated improved patient outcomes as supported by hemovigilance data in which INTERCEPT-treated platelet components prevented septic transfusion reactions. Logistics and component availability are also positively impacted resulting in cost-effective blood center operations. We look forward to working with Aalborg University Hospital in their mission for improved blood safety, and hope to extend implementation of INTERCEPT platelets to other Danish centers in the future.” ABOUT CERUS Cerus Corporationis a biomedical products company focused on enhancing blood safety. TheINTERCEPT system is designed to reduce therisk of transfusion-transmitteddiseases by inactivating a broad range of pathogens such as viruses, bacteriaand parasites that may bepresent in donated blood. The nucleic acid targetingmechanism of action enables INTERCEPT treatment to inactivate establishedtransfusionthreats, such as hepatitis B and C, HIV, West Nile virus andbacteria, and is designed to inactivate emerging pathogens such as influenza,malaria and dengue. Cerus currently markets and sells the INTERCEPT BloodSystem for both platelets and plasma in Europe, theCommonwealth of IndependentStates, the Middle East and selected countries in other regions around theworld. In the United States, Cerus is seeking regulatory approval of the INTERCEPT Blood System for plasma and platelets. The INTERCEPT red blood cell system is in clinical development. Seehttp://www.cerus.comfor more information. INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation. Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and results, including statements regarding the expected implementation schedule of the INTERCEPT platelet system at FBE Klinisk Immunologi Blodbanken. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with demand for the INTERCEPT Blood System, including the risk that purchases of the platelet system may be less than anticipated thereunder, risks relating to Cerus’ ability to meet its supply obligations, as well as other risks detailed in Cerus’ filings with the Securities and Exchange Commission, including Cerus’ Quarterly Report on Form 10-K for the quarter ended March 31, 2013 filed with the SEC on May 3, 2013. Cerus disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release. Contact: Cerus Corporation Lainie Corten, 925-288-6319 Sr Director, Global Marketing & Investor Relations
First Danish Hospital Signs INTERCEPT Platelet Agreement With Cerus
Press spacebar to pause and continue. Press esc to stop.